Hikma Pharmaceuticals (LON:HIK) Earns Hold Rating from Berenberg Bank

Berenberg Bank restated their hold rating on shares of Hikma Pharmaceuticals (LON:HIK) in a research note released on Thursday, MarketBeat reports. They currently have a GBX 2,000 ($24.70) price target on the stock.

Separately, Barclays reiterated an equal weight rating and issued a GBX 2,000 ($24.70) price target on shares of Hikma Pharmaceuticals in a research note on Monday, April 8th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and a consensus price target of GBX 2,068.75 ($25.55).

Hikma Pharmaceuticals Trading Up 3.2 %

HIK opened at GBX 1,913 ($23.63) on Thursday. The business’s 50-day simple moving average is GBX 1,887.50 and its 200-day simple moving average is GBX 1,868.77. The company has a market cap of £4.24 billion, a P/E ratio of 2,855.22, a PEG ratio of 2.38 and a beta of 0.45. Hikma Pharmaceuticals has a one year low of GBX 1,711 ($21.13) and a one year high of GBX 2,222 ($27.45). The company has a debt-to-equity ratio of 53.92, a quick ratio of 1.27 and a current ratio of 1.57.

Hikma Pharmaceuticals Increases Dividend

The company also recently declared a dividend, which will be paid on Friday, May 3rd. Investors of record on Thursday, March 21st will be paid a dividend of $0.47 per share. This represents a yield of 1.86%. The ex-dividend date is Thursday, March 21st. This is an increase from Hikma Pharmaceuticals’s previous dividend of $0.25. Hikma Pharmaceuticals’s dividend payout ratio (DPR) is currently 8,507.46%.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.